Peptide Evidence Index

Epitalon

Evidence last reviewed: September 2026

Quick answers

What is it?: Epitalon (also called Epithalon) is a synthetic four-amino-acid peptide designed to mimic part of Epithalamin, an older peptide extract made from animal pineal gland tissue. The two are chemically distinct, even though marketing often uses the names interchangeably.
Why are people interested in it?: It's sold as an anti-aging or 'geroprotective' peptide, and sellers point to human mortality studies — but nearly all of that human research tested a different, related substance, not Epitalon itself.
What has actually been studied?: Decades of animal work (mice, rats, rhesus monkeys) by one Russian/Ukrainian research group, plus human studies of Epithalamin — the related natural extract — in several hundred elderly patients followed 6-12 years. No registered or published human trial of the synthetic Epitalon peptide itself was found.
How strong is the evidence?: Early and uncontrolled. The human mortality findings come from a single research network, and available descriptions do not show randomization, double-blinding and placebo control combined together; the findings have not been independently replicated.
What don't we know yet?: Whether Epitalon itself does anything in humans at all, since almost no direct human data on the synthetic peptide exists, and whether Epithalamin's mortality findings would hold up in an independent, blinded, placebo-controlled trial.
Where can I read the original research?: Sources at the bottom of this page: Khavinson & Morozov, Neuro Endocrinology Letters 2003; Korkushko et al., Bulletin of Experimental Biology and Medicine 2006.

Plain-English overview

Epitalon is a synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly) designed to reproduce part of the activity of Epithalamin, an older peptide extract made from animal pineal gland tissue. The two are chemically different — Epithalamin is a multi-peptide natural extract, Epitalon a single synthesized molecule — but marketing routinely uses the names interchangeably. Almost the entire research trail, in animals and in the handful of human studies, comes from one research network based in St. Petersburg and Kiev, led over several decades by V. Kh. Khavinson and colleagues. Their animal studies report that both substances restore more youthful nighttime melatonin patterns and shift markers of immune and endocrine aging in old mice, rats and rhesus monkeys. Their human studies, however, are almost entirely about Epithalamin, not the synthetic Epitalon peptide sold online today. No trial of either substance is registered on ClinicalTrials.gov, and no research group outside this network has independently replicated its central findings.

What researchers are studying it for

aging / lifespan ('geroprotection')
melatonin and circadian-rhythm regulation
cardiovascular aging

Current evidence level

Early human data

Regulatory status: Not an approved medicine. Evidence strength and approval are scored separately; approval is a regulatory decision about a specific use, not a measure of how much research exists.

Human research

No trial of Epitalon or Epithalamin is registered on ClinicalTrials.gov. The human evidence that exists comes from a small number of papers by the Khavinson research network, and it is overwhelmingly about Epithalamin, the related natural pineal extract, not the synthetic tetrapeptide Epitalon actually sold today. The most-cited paper followed 266 elderly and older adults for 6 to 8 years, comparing those given Epithalamin and/or a related thymus extract (Thymalin) against a control group, and reported substantially lower mortality and fewer age-related illnesses in the treated groups; PubMed's own indexing tags this paper as a randomized controlled trial. A second paper described a '12-year randomized clinical study' of Epithalamine in elderly patients with coronary disease and accelerated cardiovascular aging, reporting a 28% lower death rate and roughly half the cardiovascular mortality in the treated group compared with control. As summarized, neither paper's methods clearly combine randomization, double-blinding and a placebo control together — the combination usually required elsewhere in medicine before a mortality claim like this is treated as reliable. No paper describing use of the synthetic Epitalon peptide itself in humans, of any design, was located. Because this entire body of work comes from one network, its findings have not been independently confirmed by outside researchers.

Animal and preclinical research

In old rhesus monkeys, Epitalon administration lowered basal blood glucose and insulin, increased nighttime melatonin, and improved glucose-tolerance measures toward the pattern seen in younger animals, in a study by the same research network. A separate rat study found that intranasal Epitalon modulated pineal cell activity (via the C-Fos protein) only under stress conditions, not under normal conditions, and reduced some stress-induced changes in pineal tissue structure. Earlier review work from the same group reported that Epitalon and Epithalamin extended lifespan in mice and fruit flies. All of this is preclinical; none of it was conducted in humans.

Major findings

Human mortality data exists only for Epithalamin, a related natural pineal extract, not for the synthetic Epitalon peptide sold today — the two are chemically distinct.
In a 266-person study followed 6 to 8 years, elderly and older adults given Epithalamin and/or Thymalin (a thymus extract) had substantially lower mortality and fewer age-related illnesses than controls.
A separate 12-year study in elderly cardiac patients reported a 28% lower death rate and roughly half the cardiovascular mortality with long-term Epithalamine treatment versus control.
In old rhesus monkeys, Epitalon reduced basal glucose and insulin levels and increased nighttime melatonin toward more youthful patterns.
In rats, intranasal Epitalon modulated pineal gland cell activity only under stress conditions and reduced some stress-related tissue changes.
No registered or published human trial of the synthetic Epitalon peptide itself, at any dose, was located.

What has not been established

Whether Epitalon, the synthetic peptide actually sold online, does anything at all in humans.
Whether Epithalamin's reported mortality reduction would hold up in an independently run, blinded, placebo-controlled trial.
What 'geroprotection' would even mean as a measurable clinical or regulatory endpoint.
What dose of the synthetic peptide, if any, would reproduce effects reported for the related extract.
What an unregulated vial sold online today actually contains.

Important limitations

Nearly all human and animal findings trace to one research network, without independent replication from outside groups.
The human studies test a different, related substance (Epithalamin) rather than the synthetic Epitalon peptide people actually take today.
As summarized, the study designs do not clearly combine randomization, double-blinding and placebo control together, the standard usually needed to trust a mortality claim.
No trial of any kind is registered on ClinicalTrials.gov, so there is no independent public record of methods or results to check.
Human study populations were narrow (elderly patients with specific conditions), which limits how the findings would apply to a general population.

Regulatory status

Epitalon is not approved as a medicine in the United States, the EU, or the UK, or in any major jurisdiction. It is sold only as an unregulated research chemical.

Primary research sources

Khavinson VKh, Morozov VG, "Peptides of pineal gland and thymus prolong human life": Neuro Endocrinology Letters 2003; PMID 14523363
Korkushko OV, Khavinson VKh, Shatilo VB, Antonyuk-Shcheglova IA, "Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging": Bulletin of Experimental Biology and Medicine 2006; PMID 17426848, DOI 10.1007/s10517-006-0365-z
Sibarov DA, Kovalenko RI, Malinin VV, Khavinson VKh, "Epitalon influences pineal secretion in stress-exposed rats in the daytime": Neuro Endocrinology Letters 2002; PMID 12500171
Goncharova ND, Vengerin AA, Khavinson VKh, Lapin BA, "Pineal peptides restore the age-related disturbances in hormonal functions of the pineal gland and the pancreas": Experimental Gerontology 2005; PMID 15664732, DOI 10.1016/j.exger.2004.10.004
Khavinson VKh, "Peptides and Ageing" (review): Neuro Endocrinology Letters 2002; PMID 12374906

Full evidence entry (complete data, registry records, dosing evidence)

Early human data

Small or uncontrolled human studies only

At a glance

Also known as: Epithalon, Epithalone, Ala-Glu-Asp-Gly
Class: Synthetic tetrapeptide
Derived from: A synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly) designed to reproduce the amino acid composition of Epithalamin, a peptide extract from animal pineal gland tissue
Registered human trials: 0
…with published results: 0
Largest human trial: None registered on ClinicalTrials.gov. No published human trial of the synthetic tetrapeptide Epitalon itself was found; the largest related human study (266 elderly patients, Khavinson & Morozov) tested a different, related preparation, Epithalamin.
Studied for: aging / lifespan ('geroprotection'), melatonin and circadian-rhythm regulation, cardiovascular aging
Dosing evidence: No human dose establishedNo controlled human trial has established an effective dose for the synthetic peptide Epitalon; what human dosing history exists is for a different, related extract (Epithalamin), given by injection in uncontrolled clinical-practice settings, not a dose-finding trial.
Regulatory status: Not approved as a medicine in the United States, the EU, or the UK. Not an approved drug in any major jurisdiction.

What it is

Epitalon (also spelled Epithalon) is a synthetic four-amino-acid peptide. It was designed to reproduce the amino acid makeup of Epithalamin, an older peptide extract made from animal pineal gland tissue. The two names are often used interchangeably in marketing, but they are chemically distinct: Epithalamin is a natural, multi-peptide extract; Epitalon is a single, synthesized tetrapeptide meant to imitate part of its activity.

What the studies actually found

The research trail behind "Epitalon" traces almost entirely to one research group, based at the St. Petersburg Institute of Bioregulation and Gerontology and the Institute of Gerontology in Kiev, led over several decades by V. Kh. Khavinson and colleagues. Their animal work — in mice, rats, and rhesus monkeys — reports that both Epithalamin and Epitalon restore a more youthful nighttime melatonin rhythm and shift markers of immune and endocrine aging in old animals.

The human studies from this group are almost all about Epithalamin, the natural extract, not the synthetic peptide Epitalon. The most-cited is a study of 266 elderly and older people followed for 6 to 8 years, reporting substantially lower mortality and fewer age-related illnesses in those given Epithalamin (alone or combined with a related thymus extract, Thymalin) compared to a control group. PubMed's own indexing tags some of these papers as "Randomized Controlled Trial," but no paper on either Epithalamin or Epitalon was found that combined randomization, double-blinding, and a placebo control all together — the combination generally required before a claim like "reduces mortality" is treated as reliable. These findings have not been independently replicated by a research group outside Khavinson's own network.

What exists in humans

No trial of Epitalon or Epithalamin is registered on ClinicalTrials.gov. The human evidence that exists is a small number of papers from a single Russian/Ukrainian research group, mostly studying the related extract (Epithalamin) rather than the synthetic peptide actually sold as "Epitalon" today. The synthetic tetrapeptide itself has been tested almost exclusively in rodents and monkeys.

What doses have been studied in humans

Almost no dosing data exists for the synthetic tetrapeptide Epitalon in humans at all — the animal studies used intramuscular or intranasal microgram-per-kilogram amounts in rats and monkeys, not in people.

The human studies that do exist used injected courses of Epithalamin — the related natural extract, not Epitalon — over periods of one to several years in elderly patients. These were not double-blind, placebo-controlled trials designed to identify a dose-response relationship; they were long-running clinical observation from a single research group. Nothing in that history establishes a dose of the synthetic peptide Epitalon that has been shown, in a controlled human trial, to do anything.

What remains unknown

Whether Epitalon, the synthetic peptide, does anything at all in humans — essentially no direct human data exists for it specifically
Whether Epithalamin's reported mortality-reduction findings would hold up in an independently run, blinded, placebo-controlled trial
What "geroprotection" would even mean as a regulatory or clinical endpoint
What an unregulated vial sold online today actually contains

Registry and study records

Peptides of pineal gland and thymus prolong human life: PubMed · Khavinson & Morozov, 2003. n=266 elderly/older adults followed 6–8 years, treated with Epithalamin and/or Thymalin vs. control. Reports substantially lower mortality. Single research group; not independently replicated.
Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging: PubMed · Korkushko et al., 2006. Described as a '12-year randomized clinical study' of Epithalamine (not Epitalon) in elderly cardiac patients; reports lower mortality vs. control. DOI: 10.1007/s10517-006-0365-z
Epitalon influences pineal secretion in stress-exposed rats in the daytime: PubMed · Sibarov et al., 2002. Explicitly distinguishes the synthetic tetrapeptide Epitalon from the natural extract Epithalamin. Rat study, not human.
Pineal peptides restore the age-related disturbances in hormonal functions of the pineal gland and the pancreas: PubMed · Goncharova et al., 2005. Rhesus monkey study of Epitalon itself — the synthetic peptide's own research base is almost entirely animal work. DOI: 10.1016/j.exger.2004.10.004

See the full Evidence Index →

Evidence last reviewed: September 2026. Peptide Proof reports what studies found. We do not give medical advice, dosing guidance, or treatment recommendations.